COVID-19
COVID-19 Information
Thank you again for standing with us in this special time when we all fight against COVID-19. We hope our online conferences can boost the communication of ocular oncology and pathology society. We also wish that the Conference provided you with productive learning and networking opportunities.
Prevention and treatment information
The virus causing COVID-19, SARS-CoV-2, is a novel pathogen [2].
It is spreading rapidly around the world and our knowledge of its behavior, its dissemination and best practices to reduce the risk of dissemination remains limited.
The treatment of malignant tumors of the eye and appendages is not considered selective treatment.
During the current COVID-19 pandemic, surgical operations on ocular tumors should be performed as far as possible for malignant tumors and some benign tumors that threaten vision. It is important to ensure that emergency patients are not unnecessarily delayed for fear of infection.
Some surgical cases are believed to carry a higher risk for transmission of SARS-CoV-2 [2]. In ocular oncology, these high-risk procedures are primarily in the oculoplastic domain.
Other COVID-19 Resources
Coronavirus and Eye Care: aao.org/coronavirus
The Academy’s coverage of and resources for the COVID-19 pandemic.
List of Urgent and Emergent Procedures
Guidance from the American Association of Ophthalmic Oncologists and Pathologists can be found at aaoop.org/corona-virus
A multi-subspecialty list can be found at aao.org/headline/list-of-urgent-emergent-ophthalmic-procedures
Reference:
[1] Peiwei Chai, Jie Yu, Shengfang Ge, Renbing Jia, Xianqun Fan. Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis. J Hematol Oncol, 2020,13:43.
Read the paper here:
Link: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00883-5
[2] Skalet AH, Allen RC, Shields CL, Wilson MW, Mruthyunjaya P, Gombos DS. Considerations for the Management and Triage of Ocular Oncology Cases during the COVID-19 Pandemic. Ocul Oncol Pathol. 2020 Apr 21;6(3):1-4. doi: 10.1159/000507734.
Read the paper here:
Link: https://www.karger.com/Article/FullText/507734
[3] COVID-19 Pandemic: Ocular Tumor Triage and Care
By Annie Stuart, Contributing Writer, interviewing Zélia Maria Corrêa, MD, PhD, J. William Harbour, MD, and Prithvi Mruthyunjaya, MD, MHS
Link: https://www.aao.org/eyenet/article/covid-19-pandemic-ocular-tumor-triage-and-care?april-2020
Research Information
Recent updates on COVID-19
Peiwei Chai, Jie Yu, Shengfang Ge, Renbing Jia, Xianqun Fan. Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis. J Hematol Oncol, 2020,13:43.
Read the paper here:
Link: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00883-5
Khanna RC, Cicinelli MV, Gilbert SS, Honavar SG, Murthy GSV. COVID-19 pandemic: Lessons learned and future directions. Indian J Ophthalmol. 2020 May;68(5):703-710. doi: 10.4103/ijo.IJO_843_20.
Read the paper here:
Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a Viral Land: A Tale of Two Pathogens. Indian J Ophthalmol. 2021 Feb;69(2):244-252. doi: 10.4103/ijo.IJO_3774_20.
Read the paper here:
Manjandavida FP, Honavar SG, Kim U, Singh U, Menon V, Das S, Kaliki S, Palanivelu MS, Khetan V, Shah PK, Rishi P, Mulay K, Gandhi A, Vadhiraja BM, Reddy VA, Bhat S, Rao V. Ocular oncology practice guidelines during COVID-19 pandemic-An expert consensus. Indian J Ophthalmol. 2020 Jul;68(7):1281-1291. doi: 10.4103/ijo.IJO_1669_20.
Read the paper here:
Link: https://journals.lww.com/ijo/Fulltext/2020/68070/Ocular_oncology_practice_guidelines_during.15.aspx